NEW YORK (GenomeWeb News) – Nanosphere today said that it has submitted a 510(k) application with the US Food and Drug Administration for its cardiac troponin I test.

The firm said that the test is used to provide early diagnosis of myocardial infarction and risk stratification for acute coronary syndromes. The test runs on the firm's Verigene molecular diagnostics platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.